SUMMARY
The decision making process in AML integrates clinical features, an increasing amount of genetic information and minimal residual disease (MRD) data. Combining these data aims at answering the following questions:
- do I treat my patient with an intensive (= curative) or a non intensive (= non-curative) approach ?
- do I have therapeutic targets to improve the current treatment?
- is there an indication for a stem cell transplantation (SCT), maintenance therapy, etc.
Each new edition of ASH brings some new answers. This was again the case at the 2016 annual ASH meeting.
(BELG J HEMATOL 2017;8(1):29–33)
